Propionic Acid

Propionic Acid

SCHEMBL4173362

CCC(=O)O.O=c1[nH]c2ccc(S(=O)(=O)N3CCCC3CN3CCCC3)cc2c2cc[nH]c12

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 1/20 0.45
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HTR7 P34969 6/20 0.42
PARP1 P09874 2/20 0.39
CASP3 P42574 5/20 0.39
CASP7 P55210 2/20 0.39
ADRA1B P35368 3/20 0.38
BACE1 P56817 1/20 0.38
BRD4 O60885 1/20 0.38
BRD2 P25440 1/20 0.38
BRD3 Q15059 1/20 0.38
BRDT Q58F21 1/20 0.38
HTT P42858 1/20 0.38
CASP9 P55211 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL4166334 1.00 KDM4E (0.45) KDM4EHSD17B10POLBPKMMEN1
Propionic Acid SCHEMBL4174066 0.84 KDM4E (0.54) KDM4EHSD17B10POLBMEN1KMT2A
SCHEMBL3249186 0.81 KDM4E (0.46) KDM4EHSD17B10POLBPKMMEN1
SCHEMBL3249189 0.81 KDM4E (0.46) KDM4EHSD17B10POLBPKMMEN1
SCHEMBL4166329 0.80 KDM4E (0.43) KDM4EHSD17B10POLBPKMMEN1
SCHEMBL4166331 0.80 KDM4E (0.43) KDM4EHSD17B10POLBPKMMEN1
Propionic Acid SCHEMBL4174097 0.79 HSD17B10 (0.55) KDM4EHSD17B10POLBMEN1KMT2A
SCHEMBL13928187 0.79 CASP3 (0.42) KDM4EHSD17B10POLBPKMMEN1
SCHEMBL3253429 0.79 CASP3 (0.42) KDM4EHSD17B10POLBPKMMEN1
SCHEMBL3251417 0.78 CASP3 (0.45) KDM4EHSD17B10POLBPKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KDM4E 1970/4885HSD17B10 3847/4885POLB 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.